Table 2.
Efficacy, cardiotoxicity and early death rate of CAG in MDS/t-AML
| Study (ref) | Year |
No. Patients * |
Median age (range) | Aclarubicin dosage | MDS/t-AML No. | CR No. | CR % | CT No. | ED No. |
| Saito [38] | 2000 | 69 | 51 (15-82) | 10 or 14 mg/m2 × 4d | 18 | 8 | 44 | 0 | 0 |
| Li [26] | 2005 | 112 | 47 (15-81) | 14 mg/m2 × 4d or 8 mg/m2 × 8d | 13 | 5 | 39 | 0 | 0 |
| Sui [56] | 2008 | 17 | NR(26-73) | 10-14 mg/m2 × 4d | 17 | 6 | 35 | 0 | 0 |
| Jin [57] | 2008 | 14 | NR(38-78) | 10-14 mg/m2 × 4d | 14 | 6 | 43 | 0 | 0 |
| Deng [58] | 2008 | 39 | NR(52-78) | 5-6 mg/m2×7d | 16 | 9 | 55 | 0 | 0 |
| Su [59] | 2009 | 33 | 60 (28-77) | 10 mg/d × 8d | 33 | 14 | 42 | 1 | 0 |
| Ni [51] | 2009 | 70 | NR(22-85) | 14 mg/m2 × 4d | 9 | 5 | 56 | 0 | 1 |
| Ma [28] | 2010 | 31 | NR(19-71) | 14 mg/m2 × 4d | 5 | 3 | 60 | 0 | 0 |
| Li [60] | 2010 | 20 | NR(36-74) | 5-7 mg/m2 × 8d | 20 | 9 | 45 | 0 | 0 |
| Zhu [61] | 2010 | 46 | 54 (31-72) | 10 mg/m2 × 8d | 28 | 13 | 46 | 0 | 0 |
| Chen [62] | 2010 | 27 | NR(21-72) | 10 mg/d × 8d | 27 | 15 | 56 | 0 | 0 |
| Liang [54] | 2010 | 54 | NR(17-82) | 5-7 mg/m2 × 8d | 15 | 5 | 33 | 0 | 2 |
Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MDS/tAML: MDS or MDS transformed AML; Ref: references; NR: not reported; *: total number of AML and MDS patients; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.